… exposure targets in ganciclovir therapy remains and to observe underexposure linked with
failure of therapy requires analysis of a wider patient population. Still, ganciclovir remains a …

… The mainstay of treatment and prevention of this infection is ganciclovir and its ester prodrug
… of routine ganciclovir therapeutic drug monitoring (TDM) as a means to optimize treatment. …

… Letermovir resistance in our two renal transplant recipients emerged after a few months
of secondary prophylaxis: In case one, letermovir resistance was detected after 106 days of …

… Lack of satisfactory virologic and clinical response after 2–3 weeks of ganciclovir treatment
suggests refractory CMV [5]. Many, but not all, refractory CMV infections are because of the …

… of ganciclovir-resistant CMV variants, despite this being biologically plausible. The molecular
determinants of ganciclovir … and ganciclovir exposure in kidney transplant recipients and to …

… a liver transplant recipient, cytomegalovirus (CMV) donor-positive (D+), recipient-negative (…
CMV infection treated with a combination therapy of letermovir and (val)ganciclovir (Figure 1). …

… A study of oral GCV in lung transplant recipients showed a significant correlation of C max
and C min with AUC, with a standard dose of 1 g three times daily [68]. However, considering …

… at the initiation of ganciclovir therapy was 79 mL/min (range 31 to 153) excluding 2 (10%) …
patients received prior to sampling was 2. Dose, frequency, and the ganciclovir treatment day …

… in solid organ and stem cell transplant recipients. Only a few … of ganciclovir and valganciclovir
in transplant recipients have … parameter to use for therapeutic drug monitoring (TDM). We …

… reviewed the pharmacokinetics of ganciclovir in patients after lung transplantation, on whom
… transplant recipients. This represents one of the largest data sets describing ganciclovir …